Loss of DNA mismatch repair: Effects on the rate of mutation to drug resistance

Journal of the National Cancer Institute

Volumn 89, Issue 20, 1997, Pages 1537-1541

  De Las Alas, Maida M ^a,b   Aebi, Stefan ^a   Fink, Daniel ^a   Howell, Stephen B ^a   Los, Gerrit ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DAUNORUBICIN; ETOPOSIDE; PACLITAXEL;

ARTICLE; BASE MISPAIRING; CANCER CELL CULTURE; CHROMOSOME 2; COLON CANCER; DNA REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE;

EID: 0030870282     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.20.1537     Document Type: Article

References (42)

1. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995;55: 2304-9.
2. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994;16:833-9.
3. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995;55: 5548-50.
4. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 1995;10:33-7.
5. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
6. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci U S A 1994;91:6319-23.
7. Kobayashi K, Matsushima M, Koi S, Saito H, Sagae S, Kudo R, et al. Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res 1996; 87:141-5.
8. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 1996;93:9049-54.
9. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995; 5:382-95.
10. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
11. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371: 75-80.
12. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, et al. Mutation in a mutL homolog in hereditary colon cancer. Science 1994;263:1625-9.
13. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homolog hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994;263: 258-61.
14. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995;55:6063-70.
15. Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC, et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995;55:4264-7.
16. Suzuki H, Komiya A, Aida S, Akimoto S, Shiraishi T, Yatani R, et al. Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res 1995; 86:956-61.
17. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996;77: 1836-43.
18. Aquilina G, Hess P, Fiumicino S, Ceccotti S, Bignami M. A mutator phenotype characterizes one of two complementation groups in human cells tolerant to methylation damage. Cancer Res 1995;55:2569-75.
19. Griffin S, Branch P, Xu YZ, Karran P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 1994;33:4787-93.
20. Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J Clin Invest 1996;98: 199-206.
21. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993;90:6424-8.
22. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995;55:3721-5.
23. Liu L, Markovitz S, Willson JKV, Gerson, SL. Mismatch repair mutator phenotype confers resistance to temozolomide in human colon cancer cell lines [abstract]. Proc Am Assoc Cancer Res 1996;37:365.
24. Fink D, Nebel S, Aebi S, Zheng H, Cenni, B, Nehme A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
25. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996;3:579-89.
26. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, et al. Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A 1996;93: 6443-7.
27. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-dichlorodiammineplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990;2:93-100.
28. Malkhosyan S, McCarty A, Sawai H, Perucho M. Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the microsatellite mutator phenotype. Mutat Res 1996;316:249-59.
29. Luria SE, Delbruk M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943;28:491-511.
30. Rossman TG, Goncharova EI, Nadas A. Modeling and measurement of the spontaneous mutation rate in mammalian cells. Mutat Res 1995;328:21-30.
31. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation [published erratum appears in Cancer Res 1995;55:201]. Cancer Res 1994;54: 4308-12.
32. Nadas A, Goncharova EI, Rossman TG. Maximum likelihood estimation of spontaneous mutation rates from large initial populations. Mutat Res 1996;351:9-17.
33. Waterman MS, Vingron M. Rapid and accurate estimates of statistical significance for sequence data base searches. Proc Natl Acad Sci U S A 1994;91:4625-8.
34. Jaffrezou JP, Chen G, Duran GE, Kuhl JS, Sikic BI. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst 1994;86: 1152-8.
35. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996;56:1091-7.
36. Chen G, Jaffrezou JP, Fleming WH, Duran GE, Sikic BI. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 1994;54: 4980-7.
37. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
38. Maxwell A, Gellert M. Mechanistic aspects of DNA topoisomerases. Adv Protein Chem 1986;38:69-107.
39. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 1989;41:223-41.
40. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665-97.
41. Vassetzky YS, Alghisi GC, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor 60.drugs. Bioessays 1995;17: 767-74.
42. Mellon I, Rajpal DK, Koi M, Boland CR, Champe GN. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996;272:557-60.